FDA Approves ANZUPGO — LEO Pharma, Inc

LEO Pharma, Inc. received FDA approval for the topical delgocitinib formulation under the brand name ANZUPGO, marking a strategic expansion of its portfolio for severe inflammatory skin diseases. Regulatory clearance for this novel, non-systemic treatment is expected to bolster the company’s commercial standing and capture a growing share of the dermatology market.